You are here

SBIR Phase II: Electronic Allergy Diagnostics: Photo-Immobilization as a General Strategy for Attaching Structurally and Compositionally Diverse Ligands onto a Single Support

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 1152483
Agency Tracking Number: 1152483
Amount: $489,496.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: BC
Solicitation Number: N/A
Timeline
Solicitation Year: 2012
Award Year: 2012
Award Start Date (Proposal Award Date): 2012-04-01
Award End Date (Contract End Date): 2014-03-31
Small Business Information
9020 SW Washington Square Rd Suite 450
Tigard, OR 97223-4436
United States
DUNS: 045283590
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Jeff King
 (503) 626-1034
 jeff.king@virogenomics.com
Business Contact
 Jeff King
Phone: (503) 626-1034
Email: jeff.king@virogenomics.com
Research Institution
 Stub
Abstract

This Small Business Innovation Research (SBIR) Phase II project aims to create better diagnostic testing for drug, food, and environmental allergies. If successful, it would be transformative in the clinical diagnosis of allergy diseases by enabling rapid evaluation at the doctor?s office in a format that is significantly preferable to skin-prick or challenge testing. The broader impacts of this research are the development of next generation diagnostic devices. These devices will enable the diagnosis of many different conditions and diseases with just a small drop of blood, right in a doctor?s office. Disease diagnosis from blood often requires that the blood sample, typically one or more test tubes full of blood, be taken from a vein in a patient?s arm and sent to a clinical laboratory. This is uncomfortable for the patient, requires them to wait days for results, is expensive, and is less safe than the approach being developed by Virogenomics because a large amount of blood that must be transported and handled. The Virogenomics platform will use just a drop of blood and will provide results while the patient is still in the doctor?s office. This diagnostic test works similar to the blood-glucose monitors diabetics use to monitor their blood sugar but is much more flexible in regards to the types of tests that can be done. In addition to allergy diagnosis, the proposed diagnostic platform would have application in many other fields that affect our health, such as diagnostics for autoimmune diseases, infectious disease and cancer.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government